Table 3.

Characteristics of studies assessing levels of TXB2 after smoking cessation.

Study	Country	Study Design	Study Participants	Treatment	Findings
Benowitz et al. [26]	US	RCT	12 healthy male smokers	Participants went through three different phases, cigarette smoking, NRT and placebo NRT. Each treatment block lasted 5 days.	TXB2 levels were 611 ± 47 pg/mg creatinine in the period of CC smoking, 479 ± 34 pg/mg creatinine in the period of transdermal nicotine application and 496 ± 33 pg/mg creatinine during the placebo treatment.
Saareks et al. [15]	Finland	Cohort	60 men and women aged 20–45 years	Fifteen smokers quit smoking without nicotine substitution, 15 used nicotine chewing gum and 30 used nicotine patches as a substitution therapy	Three days after smoking cessation without nicotine substitution, 11-dehydrothromboxane B2 levels were lowered to 75% (P < 0.01) of the initial values, and after 14 days to 50% (P < 0.01).
Rangemark et al. [37]	Sweden	Cohort	8 women aged 23–45 years	No treatment	The basal excretion of 11-DTX-B2 was 586 ± 41 pg/mg creatinine (mean ± SEM), which fell to about 350 pg/mg after smoking cessation. The fall in excretion was complete after 3 days.

RCT: randomized controlled trial.